Skip to content
Parathar, Forsteo(teriparatide)
Bonsity, Forsteo, Forteo, Parathar (teriparatide) is a protein pharmaceutical. Teriparatide was first approved as Parathar on 1987-12-23. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat osteoporosis and postmenopausal osteoporosis. The pharmaceutical is active against parathyroid hormone/parathyroid hormone-related peptide receptor. In addition, it is known to target parathyroid hormone 2 receptor.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Bonsity, Forteo (discontinued: Parathar)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Teriparatide
Tradename
Company
Number
Date
Products
BONSITYAlvogenN-211939 RX2019-10-04
1 products
FORTEOEli LillyN-021318 RX2008-06-25
1 products, RLD, RS
Show 1 discontinued
Teriparatide acetate
Tradename
Company
Number
Date
Products
PARATHARSanofiN-019498 DISCN1987-12-23
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
forteoNew Drug Application2020-11-16
teriparatideNew Drug Application2019-11-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
postmenopausal osteoporosisEFO_0003854D015663—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Teriparatide, Forteo, Lilly
75173342025-03-25DP
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H05: Calcium homeostasis
— H05A: Parathyroid hormones and analogues
— H05AA: Parathyroid hormones and analogues
— H05AA02: Teriparatide
HCPCS
Code
Description
J3110
Injection, teriparatide, 10 mcg
Clinical
Clinical Trials
157 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OsteoporosisD010024EFO_0003882M81.052015171672
Postmenopausal osteoporosisD015663EFO_000385455913536
Stress fracturesD015775M84.3——21—3
Osteogenesis imperfectaD010013Q78.0—1—2—3
Spinal cord injuriesD013119EFO_1001919—2—1—3
Chronic kidney disease-mineral and bone disorderD012080EFO_1001152N25.0——11—2
Humeral fracturesD006810EFO_0003943S42.3——11—2
Femoral fracturesD005264S72——11—2
Type 2 diabetes mellitusD003924EFO_0001360E11———1—1
Rheumatoid arthritisD001172EFO_0000685M06.9———1—1
Show 4 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypoparathyroidismD007011E20154—111
Metabolic bone diseasesD001851HP_0000938—31—15
HypocalcemiaD006996HP_0002901E83.51111——3
Endocrine system diseasesD004700EFO_0001379E34.9—12——3
Parathyroid diseasesD010279E21.5—12——3
Secondary hyperparathyroidismD006962EFO_1001173——1—12
Femoral neck fracturesD005265EFO_1001792S72.00——2——2
DialysisD003956——1——1
Hip fracturesD006620EFO_0003964S72.00——1——1
Digeorge syndromeD004062D82.1——1——1
Show 3 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colles' fractureD003100S52.53—2———2
Knee osteoarthritisD020370EFO_0004616M17—2———2
Osteoporotic fracturesD058866—2———2
Myeloid leukemia acuteD015470C92.0—1———1
Primary myelofibrosisD055728D47.4—1———1
LymphomaD008223C85.9—1———1
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.0—1———1
B-cell chronic lymphocytic leukemiaD015451C91.1—1———1
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—1———1
Hodgkin diseaseD006689C81—1———1
Show 4 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—4————4
HyperparathyroidismD006961EFO_0008506E21.32————2
Endocrine bone diseasesD0018492————2
HypercalcemiaD006934E83.521————1
PeriodontitisD010518EFO_0000649K05.31————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic kidney failureD007676EFO_0003884N18.6————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTERIPARATIDE
INNteriparatide
Description
Teriparatide is a polypeptide.
Classification
Protein
Drug classpeptides: parathyroid hormone related peptide
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C
Identifiers
PDB—
CAS-ID52232-67-4
RxCUI32915
ChEMBL IDCHEMBL525610
ChEBI ID—
PubChem CID16133850
DrugBankDB06285
UNII ID10T9CSU89I (ChemIDplus, GSRS)
Target
Agency Approved
PTH1R
PTH1R
Organism
Homo sapiens
Gene name
PTH1R
Gene synonyms
PTHR, PTHR1
NCBI Gene ID
Protein name
parathyroid hormone/parathyroid hormone-related peptide receptor
Protein synonyms
Parathyroid hormone 1 receptor, parathyroid hormone receptor 1, parathyroid hormone/parathyroid hormone-related protein receptor, PTH/PTHr receptor, PTH/PTHrP type I receptor, PTH1 receptor, seven transmembrane helix receptor
Uniprot ID
Mouse ortholog
Pth1r (19228)
parathyroid hormone/parathyroid hormone-related peptide receptor (Q80WU8)
Alternate
PTH2R
PTH2R
Organism
Homo sapiens
Gene name
PTH2R
Gene synonyms
PTHR2
NCBI Gene ID
Protein name
parathyroid hormone 2 receptor
Protein synonyms
parathyroid hormone receptor 2, PTH2 receptor
Uniprot ID
Mouse ortholog
Pth2r (213527)
parathyroid hormone 2 receptor (Q91V95)
Variants
Clinical Variant
No data
Financial
Forteo - Eli Lilly
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Teriparatide - Ligand Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 6,669 documents
View more details
Safety
Black-box Warning
Black-box warning for: Teriparatide
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
30,798 adverse events reported
View more details